EHA 2023 | GEM-SELIBORDARA: selinexor plus daratumumab, bortezomib, and dexamethasone in R/R multiple myeloma
Paula Rodriguez Otero, MD, PhD, University Clinic of Navarra, Pamplona, Spain, shares the results of the Phase II GEM-SELIBORDARA study (NCT03589222) evaluating the efficacy and safety of selinexor with daratumumab plus bortezomib and dexamethasone (DVd) in patients who were pretreated with a median of one or three prior lines of therapy. The results demonstrated encouraging efficacy, especially in patients with early relapses and who were lenalidomide-refractory. The safety profile was consistent with that of DVd and selinexor. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria from lectures: BMS, Janssen, Sanofi, GSK, Amgen, Regeneron and Takeda
Participation in Ad Board meetings: BMS, Janssen, Sanofi, Kite Pharma, Abbvie, Oncopeptides, Takeda, Pfizer and GSK
Consultant: BMS, Abbvie, Roche and Pfizer
Research funding: none
